Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Notes Payables (2016 - 2018)

Marker Therapeutics (MRKR) has disclosed Notes Payables for 4 consecutive years, with $5000.0 as the latest value for Q3 2018.

  • On a quarterly basis, Notes Payables changed 0.0% to $5000.0 in Q3 2018 year-over-year; TTM through Sep 2018 was $5000.0, a 0.0% change, with the full-year FY2017 number at $5000.0, changed 0.0% from a year prior.
  • Notes Payables was $5000.0 for Q3 2018 at Marker Therapeutics, roughly flat from $5000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $52942.0 in Q1 2015 to a low of $5000.0 in Q2 2016.
  • A 4-year average of $16988.4 and a median of $5000.0 in 2016 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: crashed 90.56% in 2016, then changed 0.0% in 2017.
  • Marker Therapeutics' Notes Payables stood at $23000.0 in 2015, then tumbled by 78.26% to $5000.0 in 2016, then changed by 0.0% to $5000.0 in 2017, then changed by 0.0% to $5000.0 in 2018.
  • Per Business Quant, the three most recent readings for MRKR's Notes Payables are $5000.0 (Q3 2018), $5000.0 (Q2 2018), and $5000.0 (Q1 2018).